The technical panel had earlier sought additional clarifications from Bharat Biotech, the manufacturer of Covaxin, in order to conduct a final Emergency Use Listing (EUL) risk-benefit assessment for global use of the vaccine.
https://ift.tt/eA8V8J The technical panel had earlier sought additional clarifications from Bharat Biotech, the manufacturer of Covaxin, in order to conduct a final Emergency Use Listing (EUL) risk-benefit assessment for global use of the vaccine. from Zee News :India National https://ift.tt/3EKWphf
No comments:
Post a Comment